

# T memory stem cells in health and disease

Luca Gattinoni<sup>1</sup>, Daniel E Speiser<sup>2</sup>, Mathias Lichterfeld<sup>3</sup> & Chiara Bonini<sup>4,5</sup>

**T memory stem (T<sub>SCM</sub>) cells are a rare subset of memory lymphocytes endowed with the stem cell–like ability to self-renew and the multipotent capacity to reconstitute the entire spectrum of memory and effector T cell subsets. Cumulative evidence in mice, nonhuman primates and humans indicates that T<sub>SCM</sub> cells are minimally differentiated cells at the apex of the hierarchical system of memory T lymphocytes. Here we describe emerging findings demonstrating that T<sub>SCM</sub> cells, owing to their extreme longevity and robust potential for immune reconstitution, are central players in many physiological and pathological human processes. We also discuss how T<sub>SCM</sub> cell stemness could be leveraged therapeutically to enhance the efficacy of vaccines and adoptive T cell therapies for cancer and infectious diseases or, conversely, how it could be disrupted to treat T<sub>SCM</sub> cell driven and sustained diseases, such as autoimmunity, adult T cell leukemia and HIV-1.**

δις γὰρ τὸν αὐτόν, ὥστε καὶ κτείν, οὐκ ἐπέλαμβανεν.

For this disease never took any man the second time so as to be mortal.

—Thucydides, *The History of the Peloponnesian War*  
(translation by Thomas Hobbes)

Immunological memory—the ability to remember and respond rapidly and more vigorously to a pathogen upon subsequent encounters—has long been recognized in human history. The first documentation of immunological memory came from the Greek historian Thucydides, who vividly described the plague that struck the city of Athens in 430 BC, recounting that “this disease never took any man the second time”<sup>1</sup>. It took us more than two millennia to understand that immunological memory is a fundamental property of the adaptive immunity conveyed by B and T lymphocytes<sup>2</sup>.

Despite the enormous progress in our understanding of basic aspects of T cell immunity, the ontogeny of memory T cells remains a matter of active debate<sup>3,4</sup>. It is clear, however, that immunological memory and protective immunity can last several decades and perhaps a lifetime, even in the absence of re-exposure to the pathogen<sup>5,6</sup>. This astonishing stability of T cell memory, despite the high cellular turnover that characterizes immune responses and the lack of replenishment of

antigen-specific T cells from hematopoietic stem cells (HSCs)—owing to constraints imposed by stochastic recombination of the T cell receptor (TCR) and thymic involution—has sparked the idea that T cell immunity could be maintained via stem cell–like memory T cells<sup>7</sup>. Over the past decade, the realization that memory T cells share a core transcriptional signature with HSCs<sup>8</sup> and display functional properties found in stem cells, such as the capacity to divide asymmetrically to generate cellular heterogeneity<sup>9</sup>, has further strengthened the view that T cells, akin to all somatic tissues, might be organized hierarchically and sustained by antigen-specific T memory stem cells<sup>10</sup>.


In this Review, we outline emerging findings demonstrating that a subset of minimally differentiated memory T cells behave as antigen-specific adult stem cells. We also discuss recent evidence placing these T<sub>SCM</sub> cells at center stage in many physiological and pathological human processes. Finally, we highlight ongoing efforts aimed at either harnessing the therapeutic potential of T<sub>SCM</sub> cells for adoptive immunotherapies or, conversely, at destabilizing the T<sub>SCM</sub> cell compartment to eliminate drug-resistant viral reservoirs or treat adult T cell leukemia and autoimmune diseases. The conceptual work and key discoveries that have shaped this field of investigation are summarized in **Figure 1**.

## The discovery of T<sub>SCM</sub> cells

Advances in multiparameter flow cytometry over the past 20 years have enabled dissection of the heterogeneity of the T cell compartment with ever-increasing precision<sup>11</sup>. In a seminal study, van Lier and colleagues identified human naive, memory and effector T cell subsets on the basis of the combinatorial expression of CD27 and CD45RA, with naive cells expressing both molecules, and memory and effector cells expressing only CD27 or CD45RA, respectively<sup>12</sup>. Subsequent work by Sallusto *et al.*<sup>13</sup> revealed the presence of two major functional subsets within the CD45RA<sup>−</sup> memory T cell pool: central memory T (T<sub>CM</sub>) cells, which express the lymph node homing molecules CCR7 and CD62L and have limited effector functions, and

<sup>1</sup>Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. <sup>2</sup>Department of Oncology, Ludwig Cancer Research, Lausanne University Hospital, Lausanne, Switzerland. <sup>3</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>4</sup>Experimental Hematology Unit, Division of Immunology Transplantation and Infectious Diseases, Leukemia Unit, San Raffaele Scientific Institute, Milan, Italy. <sup>5</sup>Hematology Department, Vita Salute San Raffaele University, Milan, Italy. Correspondence should be addressed to L.G. (gattinol@mail.nih.gov), D.E.S. (doc@dspeiser.ch), M.L. (lichterfeld@mgh.harvard.edu) or C.B. (bonini.chiara@hsr.it).

Received 31 July 2016; accepted 28 October 2016; published online 6 January 2017; doi:10.1038/nm.4241



**Figure 1** T cell stemness and  $T_{SCM}$  cells: milestones and key discoveries.  $T_{SCM}$  cells, T memory stem cells; GVHD, graft-versus-host disease; HIV-1, human immunodeficiency virus type 1; SIV, simian immunodeficiency virus; HTLV-1, human T cell lymphotropic virus type 1; CAR, chimeric antigen receptor; SNP, single-nucleotide polymorphism.

CCR7- $CD62L^-$  effector memory T ( $T_{EM}$ ) cells, which preferentially traffic to peripheral tissues and mediate rapid effector functions.

The idea that memory T cells might not be confined solely to the  $CD45RA^-$  T cell compartment, but might also be present within what was considered to be a naive T cell population, began to take shape following the identification in mice of a memory T cell population that is characterized by a naive-like phenotype, but that expresses high amounts of stem cell antigen 1 (SCA1) and the memory markers interleukin-2 receptor  $\beta$  (IL-2R $\beta$ ) and chemokine C-X-C motif receptor 3 (CXCR3)<sup>14</sup>. These cells were termed  $T_{SCM}$  cells because it was observed that they were capable of sustaining graft-versus-host disease (GVHD) upon serial transplantation into allogeneic hosts, and that they could reconstitute the full diversity of memory and effector T cell subsets while maintaining their own pool size through self-renewal<sup>14</sup>. Identifying the human counterpart of  $T_{SCM}$  cells, however, has not been straightforward, mainly owing to the lack of a human ortholog of SCA1, the prototypical marker of mouse  $T_{SCM}$  cells. Although it was known that a substantial fraction of long-lived antigen-specific  $CD8^+$  and  $CD4^+$  memory T cells displayed a naive-like phenotype ( $CD45RA^+CCR7^+CD27^+$ ) years after infection with EBV<sup>15</sup> or vaccination with attenuated smallpox or yellow fever (YF) viruses<sup>16,17</sup>, a precise set of surface markers with which to pinpoint this elusive memory phenotype in humans was missing. The breakthrough came with the demonstration that mouse  $T_{SCM}$  cells could be generated successfully *in vitro* from naive precursors by activating the Wnt- $\beta$ -catenin signaling pathway using the Wnt ligand, Wnt3a or inhibitors of glycogen synthase kinase-3 $\beta$  (ref. 18). By using this strategy to characterize extensively the phenotype of candidate human  $T_{SCM}$  cells generated *in vitro*, it was possible to identify key surface markers that can


distinguish naturally occurring human  $T_{SCM}$  cells from the naive T cell pool<sup>19</sup>. Similar to their mouse counterparts, human and nonhuman primate (NHP)  $T_{SCM}$  cells are clonally expanded cells that express a largely naive-like phenotype in conjunction with a core of memory markers, such as  $CD95$ ,  $CXCR3$ ,  $IL-2R\beta$ ,  $CD58$  and  $CD11a$ <sup>19,20</sup>. These cells represent a small fraction of circulating T lymphocytes ( $\approx 2-3\%$ ). Notably, the frequency of circulating  $T_{SCM}$  cells does not vary substantially with age<sup>21</sup>, but it seems to be heritable and associated with single-nucleotide polymorphisms (SNPs) at a genetic locus containing  $CD95$  (ref. 22), which suggests a potential role of FAS signaling in the regulation of  $T_{SCM}$  cell homeostasis.  $T_{SCM}$  cells exhibit all the defining properties of memory cells, including a diluted content of TCR excision circles, the ability to proliferate rapidly and release inflammatory cytokines in response to antigen re-exposure, and a dependence on IL-15 and IL-7 for homeostatic turnover<sup>19,23</sup>. Despite being functionally distinct from naive T cells,  $T_{SCM}$  cells share with them similar recirculation patterns and distribution *in vivo*, as evidenced by detailed compartmentalization studies in NHPs<sup>24</sup>. For instance,  $T_{SCM}$  cells are found more abundantly in lymph nodes than in the spleen and bone marrow, and they are virtually absent from peripheral mucosae<sup>24</sup>. Thus,  $T_{SCM}$  cells represent a subset of minimally differentiated T cells characterized by phenotypic and functional properties that bridge naive and conventional memory cells (Fig. 2).

### $T_{SCM}$ cells: evidence of stemness

The concept of stemness embraces the capacity both to self-renew and to generate the entire spectrum of more differentiated cells<sup>25</sup>. When Fearon and colleagues<sup>7</sup> initially postulated the existence of a stem cell pool of memory T lymphocytes, the authors pointed to  $T_{CM}$  cells

as putative T memory stem cells. This assumption was based on the evidence that  $T_{CM}$  cells are less differentiated than  $T_{EM}$  and effector cells, as shown by their longer telomeres and lower expression of perforin, granzymes and other effector molecules<sup>13</sup>. Furthermore, it was intuitive to assume that the pool of T memory stem cells should be confined to lymph nodes and secondary lymphoid organs, and  $T_{CM}$  cells were, at that time, the only antigen-experienced T cells known to express CCR7 and CD62L. The notion that  $T_{CM}$  cells might function as T memory stem cells received further support from subsequent findings that demonstrated that  $T_{CM}$  cells have superior immune-reconstitution capacity and a greater ability to persist *in vivo* than  $T_{EM}$  cells<sup>26</sup>. Recent clonogenic experiments in mice based on single-cell serial transfer have formally demonstrated the ability of mouse  $T_{CM}$  cells to self-renew and generate  $T_{EM}$  and effector progeny *in vivo*<sup>27,28</sup>. By contrast,  $T_{EM}$  cells were unable to serially reconstitute the host, even when transferred at 100-fold higher numbers, and so showed a limited capacity for self-renewal. Although these experiments did not evaluate  $T_{SCM}$  cells, these results, when combined with those of sophisticated experiments tracking T cell fates in mice through genetic barcoding<sup>29</sup> and on single naive T cell transfer<sup>30</sup>, provided strong support for the progressive model of T cell differentiation originally developed by Sallusto and Lanzavecchia<sup>31</sup>. Indeed, three separate models have been proposed to explain memory T cell differentiation<sup>3</sup>: according to the first two models, memory T cells originate from effectors either after<sup>26</sup> or before<sup>32</sup> the peak of T cell expansion. The progressive differentiation model, on the contrary, suggests that memory T cells are derived directly from naive lymphocytes upon priming, and further differentiate into shorter-lived effector subsets in a hierarchical differentiation tree, similarly to that of other organ systems<sup>31</sup> (Fig. 2). By using hematopoietic stem cell transplantation (HSCT) from haploidentical donors as a model system to study T cell differentiation, two independent groups have shown recently at polyclonal, antigen-specific and clonal levels that human  $T_{SCM}$  cells differentiate directly from naive precursors and emerge early upon *in vivo* priming<sup>33,34</sup>. By multiparametric flow cytometry and TCR sequencing, it was possible to trace and quantify the *in vivo* differentiation landscapes of transferred naive T cells, which showed that more than 30% of naive T cells undergoing priming differentiate into  $T_{SCM}$  cells<sup>33,34</sup>. Indeed, discrete T cell subsets traced across HSCT behaved preferentially within a progressive framework of differentiation. Notably, only naive T cells and  $T_{SCM}$  cells were able to reconstitute the entire heterogeneity of memory T cell subsets, including  $T_{SCM}$  cells<sup>33</sup>. A fraction of cells originally designated as  $T_{EM}$  cells reverted to a  $T_{CM}$  cell phenotype<sup>33</sup>. By contrast, only a very limited number of  $T_{CM}$  and  $T_{EM}$  cells converted to the  $T_{SCM}$  cell type<sup>33</sup>. Echoing these findings, the transfer of genetically modified virus-specific T cells reconstituted the full diversity of the T cell memory compartment—inclusive of  $T_{SCM}$ ,  $T_{CM}$  and  $T_{EM}$  cells—only when  $T_{SCM}$  cells were present within the infused cell product<sup>35</sup>. All together, these results strengthen earlier *in vitro* observations in humans<sup>19</sup> and NHPs<sup>24</sup> showing that the potential to form diverse progeny is progressively restricted as the cell type proceeds from  $T_{SCM}$  to  $T_{CM}$  and  $T_{EM}$  cells. Thus, granting some level of plasticity to the system, these data point to a progressive model of T cell differentiation, in which  $T_{SCM}$  cells are at the apex of the hierarchical tree. In line with this concept, the gene expression profile of human T cell subsets partitions  $T_{SCM}$  cells with antigen-experienced T cells and places them at a hierarchically superior level over the  $T_{CM}$  cell type<sup>19,23,36,37</sup>.

The concept of stemness also involves self-renewal and implicates long-term persistence<sup>25</sup>. The long-term persisting ability of



**Figure 2** Hierarchical model of human T cell differentiation. After antigen priming, naive T ( $T_N$ ) cells progressively differentiate into diverse memory T cell subpopulations, and ultimately, into terminally differentiated effector T ( $T_{TE}$ ) cells. T cell subsets are distinguished by the combinatorial expression of the indicated surface markers. As  $T_N$  cells differentiate progressively into the  $T_{TE}$  cell type, they lose or acquire specific functional and metabolic attributes.  $T_{SCM}$  cell, T memory stem cell;  $T_{CM}$  cell, central memory T cell;  $T_{EM}$  cell, effector memory T cell;  $\Delta\Psi_m$ , mitochondrial membrane potential.

$T_{SCM}$  and other antigen-experienced T cells cannot be addressed easily in humans because naive T cells are generated continuously, and several antigenic contacts might occur after the initial encounter. Longitudinal monitoring of genetically engineered lymphocytes infused as antigen-experienced cells, and distinguishable from endogenous lymphocytes thanks to the retroviral integration and transgene expression, has recently enabled the tracking of single T cell clonotypes over time. In patients afflicted with the adenosine deaminase (ADA)-deficient form of severe combined immunodeficiency (SCID), genetically engineered  $T_{SCM}$  cells persisted and preserved their precursor potential for decades<sup>38</sup>. Engineered lymphocytes were tracked for up to 14 years in patients with leukemia who were treated with haploidentical HSCT and donor lymphocytes transduced retrovirally to express a suicide gene<sup>35</sup>. This study revealed that the extent of expansion and the amount of persisting gene-marked T cells are tightly correlated with the number of  $T_{SCM}$  cells infused, which indicates that this subset of memory cells is endowed with enhanced proliferative potential, immune-reconstitution capacity and longevity<sup>35</sup>. Notably, the same observation has been reported in a clinical trial based on the infusion of autologous T cells that have been genetically engineered to express a chimeric antigen receptor (CAR)<sup>39</sup>, which underscores that this phenomenon is not confined to the HSCT model. In patients treated with suicide-gene therapy, it was possible to detect circulating gene-modified T cells from 2 to 14 years after treatment. Viral integration and TCR- $\alpha$  and TCR- $\beta$  clonal markers were used to trace longitudinally single, gene-modified T cell clones, sorted according to the T cell differentiation phenotype in the infused products and in patients, at long-term follow-up. It was thus possible to show that dominant T cell clones detected long term originate preferentially from infused  $T_{SCM}$  cells, and to a lesser degree, from  $T_{CM}$  clones<sup>35</sup>. Taken together, these results indicate that human  $T_{SCM}$  cells have an exceptional capacity

to persist long term. Similar conclusions were reached by monitoring T cell subset dynamics in NHP models of infection<sup>24</sup> and patients with HIV-1 undergoing antiretroviral therapy (ART)<sup>40</sup>; two experimental settings in which antigen load and time of antigen exposure can be controlled precisely. By taking advantage of the peculiar biology of the Tat-specific epitope TL8, which uniformly undergoes escape mutation within 4–5 weeks after infection with simian immunodeficiency virus (SIV), Lugli *et al.*<sup>24</sup> investigated the persistence of different memory Tat-specific T cell subsets in the virtual absence of any stimulation with antigen. In this setting, T<sub>SCM</sub> cells were able to persist at unchanged levels for up to 70 d after infection, whereas T<sub>CM</sub> and T<sub>EM</sub> cells contracted tenfold and 100-fold, respectively<sup>24</sup>. Similarly, pharmacological antigen withdrawal in ART-treated patients with HIV-1 was associated with a decline of HIV-1-specific T<sub>EM</sub> cells and terminally differentiated effector (T<sub>TE</sub>) cells, whereas the T<sub>SCM</sub> cell type gradually increased in number under these conditions<sup>40</sup>. Mirroring these findings, after YF vaccination virus-specific T<sub>TE</sub> cells underwent a more pronounced contraction than T<sub>EM</sub> cells, which in turn declined more steeply than T<sub>CM</sub> cells<sup>36</sup>. Remarkably, the frequency of YF-specific T<sub>SCM</sub> cells was maintained stably even 25 years after vaccination<sup>36</sup>. Taken together, this series of studies provides compelling evidence that human T<sub>SCM</sub> cells are generated directly from naive lymphocytes and are endowed with long-term self-renewal capacity and multipotency.

### T<sub>SCM</sub> cells in host defense

Pathogen-specific T<sub>SCM</sub> cells have been increasingly identified in human acute and chronic infections caused by viruses, bacteria and parasites<sup>19,35,36,40–42</sup>. These results demonstrate that T<sub>SCM</sub> cells are commonly generated during natural immune responses against foreign pathogens, but the underlying mechanisms remain poorly understood. Human studies are limited in that the exact time of infection is usually unknown, which makes it difficult to study T cell priming and kinetics. By contrast, active vaccination offers the possibility of inducing an immune response in a supervised fashion. Smallpox and YF vaccines are particularly suitable models of human primary acute viral infection because they consist of live, attenuated, replication-competent viruses capable of inducing strong immune responses with consequent clinical symptoms<sup>43</sup>. By using YF vaccination as a model system, the kinetics of T<sub>SCM</sub> cell formation and long-term maintenance have recently been studied in great detail<sup>36</sup>. Consistent with findings from studies of SIV infection in NHPs<sup>24</sup>, YF-specific T<sub>SCM</sub> cells were detectable at early time points after vaccination when the immune response was dominated by effector T cells<sup>36</sup>. These T<sub>SCM</sub> cells persisted at stable levels and became the major YF-specific memory T cell population in the circulation decades after the initial immunization<sup>36</sup>. Considering that YF vaccination provides life-long protection<sup>43</sup>, it is reasonable to assume that T<sub>SCM</sub> cells have a central role in the maintenance of long-term T-cell memory.


The presence of a relevant pool of T<sub>SCM</sub> cells might also be essential for the control of persisting infections, in which effector T cells undergoing functional exhaustion and replicative senescence need to be replenished continuously by less differentiated T cell subsets<sup>44–47</sup>. Notably, recent studies in chronic viral<sup>40,48</sup> and parasitic infections<sup>42</sup> revealed a negative correlation between the severity of disease and the frequency of circulating T<sub>SCM</sub> cells. It is unclear whether these observations result from the inability of T<sub>SCM</sub> cells to be maintained under conditions of strong inflammation and high antigenic load, or vice versa, that the presence of insufficient numbers of T<sub>SCM</sub> cells impairs the ability of the immune system to control pathogen

replication. However, emerging findings suggest that T<sub>SCM</sub> cells are crucial to the maintenance of immune homeostasis; high levels of infection of the T<sub>SCM</sub> cell compartment and its subsequent functional perturbation have been linked to the development of symptomatic immune deficiency following SIV and HIV-1 infections<sup>49,50</sup>. Indeed, high quantities of SIV DNA were found in CD4<sup>+</sup> T<sub>SCM</sub> cells from rhesus macaques, who typically develop an AIDS-like clinical picture when left untreated, but they were not found in CD4<sup>+</sup> T<sub>SCM</sub> cells from SIV-infected sooty mangabeys, a group of NHPs that are refractory to clinical or laboratory signs of immune deficiency even when high levels of virus circulate in the peripheral blood<sup>49,51,52</sup>. Resonating with this observation, viremic nonprogressors—a rare group of untreated patients with HIV-1 who develop high levels of HIV-1 replication in the absence of clinical immune deficiency—exhibit reduced levels of HIV-1 DNA in CD4<sup>+</sup> T<sub>SCM</sub> cells in comparison to patients with HIV-1 who show ordinary rates of disease progression<sup>50</sup>. All together, these results underscore a crucial function of T<sub>SCM</sub> cells in the sustenance of long-lasting cellular immunity against acute and chronic microbial infections.

Given the pivotal role of T<sub>SCM</sub> cells in the maintenance of life-long immunological memory, it would be desirable to develop vaccines that are capable of inducing substantial numbers of T<sub>SCM</sub> cells. The majority of clinical vaccine formulations designed to stimulate CD8<sup>+</sup> T cell-mediated immunity induce predominantly T<sub>EM</sub>, and few memory, cells<sup>53,54</sup>. These vaccines are rarely efficacious as compared to those that induce protective antibodies<sup>2,55</sup>. Indeed, current T cell vaccines seem inefficient at triggering mechanisms that are key for the development of memory T cells, including optimal signaling via the TCR and the induction of appropriate metabolic programs, transcription factors and chromatin reorganization<sup>56</sup>. Considering that the activation of CD8<sup>+</sup> T cells under conditions of low-level inflammation enhances memory cell formation, one might surmise that vaccines should, ideally, stimulate T cells without triggering the excessive release of proinflammatory cytokines<sup>57</sup>. It is, however, debatable whether optimal generation of memory T cells requires the avoidance of effector cell differentiation. This is illustrated by the fact that natural infections generate sound memory T cell responses, including T<sub>SCM</sub> cells, despite the initial predominance of effector cells<sup>43</sup>. Indeed, the emergence of T<sub>SCM</sub> cells was recently observed after the administration of a subunit cancer vaccine capable of inducing a rapid and robust expansion of effector T cells<sup>58</sup>. Much work remains to be done in this area; however, the induction of T<sub>SCM</sub> cells by novel vaccines should not be at the expense of more differentiated T<sub>EM</sub> and tissue-resident memory cells, which assure immediate protection at the entry site of re-infection in peripheral tissues<sup>59–61</sup>. Ideally, new vaccines will be able to recreate the full spectrum of memory cell phenotypes that human pathogens and their pathophysiological properties induce *in vivo*<sup>62,63</sup>.

### T<sub>SCM</sub> cells can exacerbate human disease

The complex biology of T<sub>SCM</sub> cells can make it difficult to discriminate between their protective and pathogenic effects because the very characteristics that enable T<sub>SCM</sub> cells to represent the backbone of life-long cellular immunity under physiologic conditions might empower these cells to drive disease pathogenesis<sup>64</sup>. This seems particularly relevant in the setting of a growing list of immune-mediated diseases associated with aberrant and autoreactive memory T cells. For instance, recent correlative studies have suggested an increased frequency and activation state of CD8<sup>+</sup> T<sub>SCM</sub> cells in individuals with aplastic anemia, a disease mediated by autoreactive cytotoxic T cells targeting hematopoietic progenitors, as compared to healthy individuals<sup>65</sup>.



**Figure 3** T<sub>SCM</sub>-cell-based therapeutic interventions for human diseases. T<sub>SCM</sub> cells can be either disrupted (left) to treat T<sub>SCM</sub>-driven diseases, such as autoimmunity, T cell leukemia and T cell tropic infections, or exploited (right) to potentiate T cell-based immunotherapies against cancer and infectious diseases. Left, Wnt antagonists or short hairpin RNA (shRNA) targeting key molecules involved in Wnt signaling, such as T cell factor 7 (TCF7) could be used to disrupt long-lasting, self-renewing T<sub>SCM</sub> cell reservoirs by driving them to differentiate into short-lived subsets, such as T<sub>EM</sub> cells. Nanoparticle or aptamer technology could be employed to target CD4<sup>+</sup> T cells or virally infected T cells specifically. Right, patient- or donor-derived naive-like T cells can be used to generate and expand T<sub>SCM</sub> cells *in vitro* with or without gene engineering. Gene modifications include the insertion of tumor or virus-specific chimeric antigen receptor (CAR) or T cell receptor (TCR) genes, tumor or virus-specific TCR gene editing, suicide-gene transfer for the option to eliminate the transferred T<sub>SCM</sub> cells and their progeny in case of overwhelming toxicity, and CCR5 gene editing in the setting of HIV-1 infection. Virus-specific T<sub>SCM</sub> cells can also be expanded from the naturally occurring antigen-specific TCR repertoire through sensitization protocols *in vitro* favoring the generation of T<sub>SCM</sub> cells. APC, antigen-presenting cell.

Moreover, an elevated number of CD8<sup>+</sup> T<sub>SCM</sub> cells after immunosuppressive treatment was associated with treatment failure and subsequent aplastic anemia relapse<sup>65</sup>. Elevated numbers of T<sub>SCM</sub> cells were also noted in patients with uveitis, but not in those with systemic lupus erythematosus, an immune-mediated disease characterized primarily by autoreactive humoral responses<sup>65</sup>. Further pointing toward a role of T<sub>SCM</sub> cells in the pathogenesis of autoimmune diseases and other illnesses of the lymphatic system, a recent genome-wide association study found a strong association between genetic polymorphisms affecting susceptibility to juvenile idiopathic arthritis or chronic lymphocytic leukemia, and the frequency of CD4<sup>+</sup> T<sub>SCM</sub> cells<sup>22</sup>. How T<sub>SCM</sub> cells can influence autoimmune diseases will have to be studied in dedicated investigations, but on the basis of current knowledge, it is reasonable to hypothesize that long-lasting autoreactive or abnormally activated T<sub>SCM</sub> cells might induce self-renewing inflammatory cellular responses that are responsible for the durable, and in most cases life-long, persistence of such diseases<sup>66</sup>. The possible role of T<sub>SCM</sub> cells in other diseases with profound disturbance of cellular immune responses, such as autoimmune hepatitis, thyroiditis, type 1 diabetes and certain types of glomerulonephritis, are currently unknown but represent a high priority area of future research.

In addition to their role in autoimmunity, T<sub>SCM</sub> cells might have a distinct role in viral diseases in which T cells represent the

predominant targets, such as infections caused by CD4<sup>+</sup> T cell tropic retroviruses. Notably, work in the context of HIV-1 infection has shown that CD4<sup>+</sup> T<sub>SCM</sub> cells can effectively support both productive viral replication and a transcriptionally silent form of infection<sup>67</sup>. Moreover, by infecting long-lived CD4<sup>+</sup> T<sub>SCM</sub> cells, HIV-1 is able to exploit their stemness to establish an extremely durable, self-renewing viral reservoir that can persist for decades, despite ART, and continuously replenish virally infected cells, thus perpetuating a disease that they are meant to restrict<sup>68</sup>. Indeed, the half-life of HIV-1-infected T<sub>SCM</sub> cells in ART-treated individuals has been estimated to be around 277 months, a time period substantially longer than that observed for viral reservoirs established in more short-lived T cell populations<sup>69</sup>. In line with these observations, phylogenetic studies demonstrated close associations between viruses circulating early after HIV-1 infection and viral sequences isolated from CD4<sup>+</sup> T<sub>SCM</sub> cells after almost a decade of suppressive ART<sup>68</sup>. Notably, the ability to use CD4<sup>+</sup> T<sub>SCM</sub> as a long-term viral reservoir also seems to occur in individuals infected with HTLV-1, a retrovirus related to HIV-1 that is the primary cause of adult T cell leukemia (ATL). Emerging data indicate that transformed, HTLV-1 infected CD4<sup>+</sup> T<sub>SCM</sub> cells can act as progenitors for dominant circulating ATL clones and can efficiently propagate ATL upon transplantation in animal models<sup>70</sup>. This suggests that they can serve as a cancer stem

cell population responsible for the propagation and maintenance of HTLV-1-infected malignant cells.

### Targeting T<sub>SCM</sub> cells for therapy

**Harnessing T<sub>SCM</sub> cells for adoptive T cell therapy.** The extreme longevity, the robust proliferative potential and the capacity to reconstitute a wide-ranging diversity of the T cell compartment make the T<sub>SCM</sub> cell type an ideal cell population to employ in adoptive immunotherapy (Fig. 3). Driven by the growing success of clinical trials that are based on the transfer of naturally occurring and genetically engineered tumor-reactive T lymphocytes, adoptive immunotherapies are rapidly becoming a real therapeutic option for patients with cancer<sup>71,72</sup>. Although these regimens can induce complete and durable tumor regressions in patients with advanced cancer, current response rates remain mostly inadequate, which underscores the need for further improvements<sup>71,72</sup>. There is now extensive evidence indicating that objective responses are strongly correlated with the level of T cell engraftment and peak of expansion early after transfer<sup>73–79</sup>. T cell persistence, although not strictly indispensable in certain conditions<sup>74–77,80</sup>, has also been associated with the likelihood of objective responses in numerous trials<sup>78,79,81–85</sup> and might be required to sustain durable remissions<sup>86</sup>. These parameters are influenced considerably by the composition of the infused T cell product because T cell subsets differ widely in terms of proliferative capacity, immune reconstitution and long-term survival<sup>10,87</sup>. Indeed, the administration of cells with longer telomeres<sup>83,88</sup> or cell products comprising higher fractions of CD62L<sup>+</sup>, CD28<sup>+</sup> or CD27<sup>+</sup> T cells has been shown to correlate with objective tumor responses in patients<sup>83,88–90</sup>, which suggests that less differentiated T cells are therapeutically superior to T<sub>TE</sub> cells. Notably, the engraftment and expansion of T cells engineered to express a CD19-specific CAR<sup>39</sup> or a suicide gene<sup>35</sup> was correlated with the frequency of infused CD8<sup>+</sup>CD45RA<sup>+</sup>CCR7<sup>+</sup> T<sub>SCM</sub> cells. Adoptive transfer experiments in mice, using defined T cell subsets, have demonstrated formally that the infusion of less-differentiated CD62L<sup>+</sup> T cell populations results in enhanced T cell engraftment, expansion and persistence, which leads ultimately to more profound and durable tumor regressions<sup>18,19,91–95</sup>. Consistent with the developmental hierarchy, minimally differentiated T<sub>SCM</sub> cells mediate more potent antitumor responses than T<sub>CM</sub> cells, which, in turn, are more effective than highly differentiated T<sub>EM</sub> cells<sup>18,19,96</sup>. Some level of plasticity, however, must be granted to the hierarchical model of memory T cell differentiation. In NHPs, genetically engineered CMV-specific effectors derived from purified T<sub>CM</sub> cells proved superior to effectors derived from T<sub>EM</sub> cells in terms of expansion and persistence *in vivo*, which shows that even after manipulation *in vitro* and, apparently, a similar degree of terminal differentiation, T cells maintain some characteristics of the subset of origin, and can possibly, at least in part, revert to that original phenotype and function<sup>97</sup>.

Despite overwhelming preclinical data indicating a therapeutic advantage to transferring tumor-reactive CD62L<sup>+</sup> T cell subsets<sup>18,19,91–95</sup>, clinical trials have largely employed unselected intratumoral or peripheral blood mononuclear cell (PBMC)-derived T cell populations. Tumor-infiltrating lymphocytes are typically in a state of terminal differentiation and functional exhaustion, which makes the isolation of early memory T cell subsets impractical<sup>98,99</sup>. However, the selection of less differentiated T cell subsets becomes realistic and desirable in the context of immunotherapies that are aimed at conferring tumor reactivity to circulating T cells via TCR or CAR gene engineering. The isolation of less differentiated T cell populations also has the advantage of reproducibly generating more

defined T cell products. Indeed, PBMC composition can vary substantially between individuals as a consequence of age<sup>100</sup>, pathogen exposure<sup>101</sup> and prior systemic treatments<sup>102</sup>. Moreover, unselected populations containing high proportions of T<sub>EM</sub> and effector cells might fail to generate viable clinical products owing to poor *in vitro* cell expansion<sup>103</sup>. Recently, a few clinical trials in which CD19-specific CAR T cells were generated from isolated T<sub>CM</sub> cells have been reported<sup>86,104,105</sup>. This strategy led to the generation of infusion products composed of substantially more T<sub>EM</sub> cells than those originating from unselected PBMCs, which indicates that, in the absence of culture conditions restraining T cell differentiation<sup>18,106–110</sup>, the benefit of depleting highly differentiated T cell subsets is outweighed by the concomitant removal of naive and T<sub>SCM</sub> cells<sup>104</sup>. Notwithstanding the reduction of less differentiated T cell subsets, the rates of objective remissions in patients with acute lymphoblastic leukemia (ALL) were comparable to results of trials that used unselected T cell populations<sup>74,75,78,104,111,112</sup>. Whether differences in manufacturing and T cell product composition will affect the rates and duration of clinical responses in other diseases and settings remains to be shown.

So far, the clinical exploitation of T<sub>SCM</sub> cells has been hindered by their relative paucity in the circulation<sup>19,20</sup> and the lack—until recently—of robust, clinical-grade manufacturing protocols that are capable of generating and maintaining this cell type *in vitro*. These strategies rely on programming and redirecting T<sub>SCM</sub> cells from naive-like T cells isolated from PBMCs<sup>23,113</sup> (Fig. 3). Although the isolation of naive T cells adds complexity to the manufacturing process, it is a crucial step because the presence of more differentiated T cell subsets during naive T cell stimulation accelerates naive T cell differentiation into T<sub>EM</sub> and T<sub>TE</sub> cells<sup>114</sup>. It should also be considered that purifying large numbers of specific cell subsets over multiple parameters under good manufacturing practice conditions is becoming increasingly accessible thanks to recent developments in clinical cell-sorting technologies<sup>87,115</sup>. IL-7 and IL-15 have been used successfully to generate tumor-redirected or suicide-gene-modified T<sub>SCM</sub> cells from naive cell precursors<sup>23</sup> (Fig. 3). IL-7 is essential for the development of these cells<sup>23,116</sup>, whereas IL-15 primarily sustains their expansion<sup>23</sup>. IL-7 and IL-15-programmed T<sub>SCM</sub> cells possess a core gene signature of naturally occurring T<sub>SCM</sub> cells, display an enhanced proliferative capacity as compared to other T cell subsets and are uniquely capable of expanding and mediating GVHD upon serial transplantation<sup>23</sup>. This cytokine combination could also be employed to generate large numbers of TCR-gene-edited T<sub>SCM</sub> cells by combining zinc-finger nuclease sets specific for the endogenous TCR gene loci with viral vectors encoding tumor-specific TCRs<sup>117</sup> (Fig. 3). Moreover, the ability of IL-7 and IL-15 to support the formation and expansion of T<sub>SCM</sub> cells makes it an ideal strategy for generating T<sub>SCM</sub> cells without the need to redirect their specificity. This might be particularly suitable for the generation of virus-specific T<sub>SCM</sub> cells for the treatment and prevention of life-threatening infections after transplantation (Fig. 3), given that infection control can be obtained by transferring relatively small numbers of virus-specific memory cells<sup>118</sup>. A demonstration that IL-7 and IL-15 could be employed successfully to generate and expand virus-specific T<sub>SCM</sub> cells, starting from isolated naive-like cells, was provided recently by Volk and colleagues<sup>119</sup>. This protocol could also be adapted to generate CAR-modified virus-specific T<sub>SCM</sub> cells, which might lower the risk of GVHD, given the restricted TCR repertoire, and which may exhibit additional proliferative and survival advantages as a result of the triggering *in vivo* of the native virus-specific TCRs by antigens from

### Box 1 T<sub>SCM</sub> cell biology: outstanding questions

Several questions regarding T<sub>SCM</sub> cell biology remain unresolved. A major issue is how T<sub>SCM</sub> cells form during infection. Is T<sub>SCM</sub> cell fate programmed at the time of naive T cell priming, or is it shaped throughout multiple antigen encounters and the diverse inflammatory environments that their progeny experience? A glimpse into T<sub>SCM</sub> cell transcriptional and epigenetic landscapes<sup>19,36,37,137,138</sup> and metabolism<sup>113,137</sup> has begun to reveal the molecular and metabolic programs of T<sub>SCM</sub> cells. Whether asymmetric partitioning of key transcription factors<sup>139,140</sup> and metabolic master regulators<sup>141,142</sup> is programming T<sub>SCM</sub> cell formation is unknown. Additionally, T<sub>SCM</sub> cell anatomical niches remain elusive. Progress has been hampered by the rarity of T<sub>SCM</sub> cells, which limits epigenetic, proteomic and metabolomic studies. The lack of mouse models of infection that are capable of generating robust numbers of T<sub>SCM</sub> cells has precluded researchers from evaluating specific gene contributions to T<sub>SCM</sub> cell physiology with genetic tools, and from imaging T<sub>SCM</sub> cell dynamics within tissues by real-time microscopy.

**T<sub>SCM</sub> cell epigenetic and transcriptional programs.** Transcriptomic analyses of whole<sup>19,137</sup> and YF-specific T<sub>SCM</sub> cells<sup>36,37</sup> have revealed that this cell type is closely related to T<sub>CM</sub> cells. These findings suggest that the majority of transcriptional pathways shaping T<sub>CM</sub> cell development and maintenance might also regulate T<sub>SCM</sub> cells. For instance, Wnt-β-catenin signaling is essential for T<sub>CM</sub> cell formation and survival<sup>143–146</sup>, but is also crucial for the generation of T<sub>SCM</sub> cells<sup>18,19,113</sup>. Likewise, tempering mTOR signaling enhances the development of both T<sub>CM</sub><sup>147,148</sup> and T<sub>SCM</sub> cells<sup>137</sup>. Whether specific transcriptional networks are uniquely activated to influence T<sub>SCM</sub> cell fate is unknown. It is also unclear what role CD95–FAS ligand signaling in T<sub>SCM</sub> cell homeostasis has. Overlaying the transcriptome is the undefined T<sub>SCM</sub> cell epigenetic program. Genome-wide analysis of histone methylation in naive and *in vitro*-generated mouse CD8<sup>+</sup> T cell subsets, including T<sub>SCM</sub> cells, have revealed that chromatin accessibility is mostly regulated in a progressive fashion<sup>138</sup>, but that confirmation in *ex vivo*-isolated cells is warranted.

**T<sub>SCM</sub> cell metabolism.** Metabolism is intimately linked to T cell activity and fate<sup>149</sup>. Fatty acid oxidation, increased mitochondrial biomass and spare respiratory capacity support the development and function of memory T cells<sup>127,150</sup>. Conversely, aerobic glycolysis favors terminal-effector differentiation, limiting T cell memory formation<sup>128</sup>. Emerging findings indicate that naturally occurring and *in vitro*-generated T<sub>SCM</sub> cells also exhibit the ‘metabolic signature’ of conventional memory cells<sup>113,137</sup>. Recently, HSC and T cell stemness have been linked to decreased mitochondrial membrane potential ( $\Delta\Psi$ )<sup>151</sup>. Analogously, T<sub>SCM</sub> cells display lower  $\Delta\Psi$  than other antigen-experienced T cell subsets<sup>137,151</sup>. Whether T<sub>SCM</sub> cells maintain the fused mitochondrial networks with tight cristae organization seen in conventional memory T cells<sup>152</sup> remains to be determined. Future areas of research include the role of amino acids and a global characterization of the T<sub>SCM</sub> cell metabolome.

**T<sub>SCM</sub> cell anatomical niches.** Stem cell niches are instrumental in the regulation of stem-cell behavior and tissue homeostasis, guiding HSCs to either self-renew or differentiate<sup>153</sup>. Accumulating evidence underscores the crucial role of the bone marrow in sustaining the persistence of memory T cells<sup>154–157</sup>. Whether the bone marrow similarly serves as a T<sub>SCM</sub> cell niche is a fundamental question. Alternatively, akin to naive T cells<sup>158</sup>, T<sub>SCM</sub> cells might rely on homeostatic cues provided by fibroblastic reticular cell niches within lymph nodes. Finally, the characterization of contact-dependent cross-talk, cytokine networks and metabolite constituents regulating T<sub>SCM</sub> cells in their niches remains to be addressed.

persistent viruses<sup>82,120</sup>. Another clinical-grade strategy promoting the generation of tumor-reactive T<sub>SCM</sub> cells is based on the activation of naive-like lymphocytes in the presence of IL-7, IL-21 and the Wnt agonist TWS119 (ref. 113). Although both IL-15 (refs. 121,122) and IL-21 (refs. 123–125) have been implicated in the generation and maintenance of memory T cells, IL-21 is more effective in restraining T cell differentiation<sup>107</sup>, owing to its specific ability to activate signal transducer and activator of transcription 3 (STAT3) signaling<sup>126</sup> and to sustain the expression of the Wnt-β-catenin transcription factors *TCF7* and *LEF1* (ref. 107). TWS119 has a synergistic effect with IL-21 to induce maximal expression of *TCF7* and *LEF1* by stabilizing β-catenin<sup>113</sup>. CAR-modified T<sub>SCM</sub> cells generated under these culture conditions are phenotypically, functionally and transcriptionally equivalent to their naturally occurring counterparts<sup>113</sup>. Moreover, they exhibit metabolic features, such as a high spare respiratory capacity<sup>127</sup> and low glycolytic metabolism<sup>128</sup>, that are characteristic of long-lived memory T cells. Although these culture conditions profoundly inhibit T cell proliferation, T<sub>SCM</sub> cells can be redirected efficiently against a tumor antigen and expanded to clinically relevant numbers<sup>113</sup>. More importantly, CAR-modified CD8<sup>+</sup> T<sub>SCM</sub> cells mediated superior and more durable anti-tumor responses than cells generated with protocols currently employed in clinical trials<sup>113</sup>. CAR-modified T<sub>SCM</sub> cells might also provide an attractive

approach for immunotherapy in the setting of nonmalignant diseases, such as HIV-1 infection or other chronic viral illnesses<sup>129,130</sup> (Fig. 3). All together, these studies provide both a strong scientific rationale and practical methodologies for the rapid advancement of T<sub>SCM</sub> cells in human clinical trials of adoptive immunotherapy<sup>131</sup>.

*Disrupting T<sub>SCM</sub> cell reservoirs in retroviral infections and autoimmune diseases.* The emerging role of CD4<sup>+</sup> T<sub>SCM</sub> cells in the pathogenesis of chronic viral infections such as HIV-1 and HTLV-1 infection might also offer novel opportunities to prevent, treat or cure these diseases. In the context of HIV-1 infection, specific interventions that eliminate HIV-1-infected CD4<sup>+</sup> T<sub>SCM</sub> cells might allow for the destabilization of HIV-1 reservoirs by reducing the number of HIV-1-infected source cells from which new HIV-1<sup>+</sup> viral and cellular progeny can continuously originate, despite suppressive ART. As the molecular programs that govern the stem cell-like behavior of T<sub>SCM</sub> cells continue to be understood, new molecules regulating proliferation and self-renewal of T<sub>SCM</sub> cells might represent attractive targets for reducing viral persistence in CD4<sup>+</sup> T<sub>SCM</sub> cells. For instance, Wnt-β-catenin signaling has been identified as a key driver for the homeostasis of T<sub>SCM</sub> cells<sup>18</sup>, and pharmaceutical inhibition of this pathway might therefore translate into a more limited ability of HIV-1 to use the T<sub>SCM</sub> compartment for maintaining the survival of virally infected cells (Fig. 3). This approach might be facilitated by the availability

of existing pharmacological inhibitors of Wnt- $\beta$ -catenin designed to target cancer stem cells<sup>132</sup>. Although such a strategy might be not entirely specific to the elimination of HIV-1-specific CD4<sup>+</sup> T<sub>SCM</sub> cells, advances in nanotechnology might enable selective delivery of Wnt- $\beta$ -catenin antagonists or short hairpin RNAs targeting key mediators of Wnt signaling to CD4<sup>+</sup> T cells or virally infected cells via nanoparticles or aptamer-based targeting systems<sup>133,134</sup> (Fig. 3). Similar strategies are also conceivable for targeting HTLV-1-infected T<sub>SCM</sub> cells in the setting of ATL or to disrupt long-lasting reservoirs of autoreactive T<sub>SCM</sub> cells in autoimmune diseases. Additionally, recent advances in gene editing *ex vivo* might enable the design of CD4<sup>+</sup> T<sub>SCM</sub> cells that are intrinsically resistant to HIV-1, through, for example, targeted deletion of the chemokine receptor CCR5, which is necessary for viral entry<sup>135</sup>, thus mimicking the CCR5 $\Delta$ 32 mutation known to confer resistance to HIV-1 infection<sup>136</sup> (Fig. 3). Such a population of long-lasting, HIV-1-resistant CD4<sup>+</sup> T cells could be used in adoptive immunotherapy strategies to establish a durable cellular immune system that is no longer able to support HIV-1 infection and that might lead to drug-free remission of HIV-1 infection.

### Concluding remarks

T<sub>SCM</sub> cells are rare, antigen-experienced T cells, probably generated directly from naive lymphocytes and endowed with long-term self-renewal capacity and multipotency. Compelling evidence in mice, NHPs and humans points toward a scenario in which T<sub>SCM</sub> cells represent the apex of the memory T cell differentiation tree. Their longevity and their capacity to reconstitute the entire heterogeneity of the T cell memory compartment entail a double-edged—protective or pathogenic—role for T<sub>SCM</sub> cells in human diseases. Their increasingly recognized protective role in acute and chronic infections makes them optimal candidates for therapeutic exploitation in vaccination and adoptive T cell therapy against infectious diseases and cancer. Conversely, their relevance in the pathogenesis of autoimmunity, adult T cell leukemia and HIV-1 makes them an attractive target to tame for these pathological conditions. Several issues regarding T<sub>SCM</sub> cell biology remain to be addressed: characterization of their metabolic requirements, epigenetic and transcriptional programs and anatomical niches (Box 1) will guide innovative T<sub>SCM</sub> cell-based therapeutic interventions for human diseases.

### ACKNOWLEDGMENTS

This work was supported by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research (ZIA BC011480), the 2014 US National Institutes of Health (NIH) Bench-to-Bedside Award, (to L.G.) NIH grants AI098487, AI106468, AI114235, AI117841, AI120008, AI124776 (to M.L.), the Cancer Research Institute (N.Y.), the Ludwig Cancer Research (N.Y.), the Swiss Cancer League (3507-08-2014), the Swiss National Science Foundation (320030\_152856, CRSII3\_160708), the SwissTransMed (KIP 18) (to D.E.S.), the Italian Association for Cancer Research and the SUPERSIST (EU-FP7 project) (to C.B.).

### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

1. Thucydides & Hobbes, T. *Peloponnesian Warre* (Charles Harper, London, 1676).
2. Sallusto, F., Lanzavecchia, A., Araki, K. & Ahmed, R. From vaccines to memory and back. *Immunity* **33**, 451–463 (2010).
3. Ahmed, R., Bevan, M.J., Reiner, S.L. & Fearon, D.T. The precursors of memory: models and controversies. *Nat. Rev. Immunol.* **9**, 662–668 (2009).
4. Restifo, N.P. & Gattinoni, L. Lineage relationship of effector and memory T cells. *Curr. Opin. Immunol.* **25**, 556–563 (2013).

5. Demkowicz, W.E. Jr., Littaua, R.A., Wang, J. & Ennis, F.A. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. *J. Virol.* **70**, 2627–2631 (1996).
6. Hammarlund, E. *et al.* Duration of antiviral immunity after smallpox vaccination. *Nat. Med.* **9**, 1131–1137 (2003).
7. Fearon, D.T., Manders, P. & Wagner, S.D. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. *Science* **293**, 248–250 (2001).
8. Luckey, C.J. *et al.* Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. *Proc. Natl. Acad. Sci. USA* **103**, 3304–3309 (2006).
9. Ciocca, M.L., Barnett, B.E., Burkhardt, J.K., Chang, J.T. & Reiner, S.L. Cutting edge: Asymmetric memory T cell division in response to rechallenge. *J. Immunol.* **188**, 4145–4148 (2012).
10. Gattinoni, L., Klebanoff, C.A. & Restifo, N.P. Paths to stemness: building the ultimate antitumor T cell. *Nat. Rev. Cancer* **12**, 671–684 (2012).
11. Chattopadhyay, P.K., Gierahn, T.M., Roederer, M. & Love, J.C. Single-cell technologies for monitoring immune systems. *Nat. Immunol.* **15**, 128–135 (2014).
12. Hamann, D. *et al.* Phenotypic and functional separation of memory and effector human CD8<sup>+</sup> T cells. *J. Exp. Med.* **186**, 1407–1418 (1997).
13. Sallusto, F., Lenig, D., Förster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* **401**, 708–712 (1999).
14. Zhang, Y., Joe, G., Hexner, E., Zhu, J. & Emerson, S.G. Host-reactive CD8<sup>+</sup> memory stem cells in graft-versus-host disease. *Nat. Med.* **11**, 1299–1305 (2005).
15. Long, H.M. *et al.* MHC II tetramers visualize human CD4<sup>+</sup> T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. *J. Exp. Med.* **210**, 933–949 (2013).
16. Miller, J.D. *et al.* Human effector and memory CD8<sup>+</sup> T cell responses to smallpox and yellow fever vaccines. *Immunity* **28**, 710–722 (2008).
17. Akondy, R.S. *et al.* The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8<sup>+</sup> T cell response. *J. Immunol.* **183**, 7919–7930 (2009).
18. Gattinoni, L. *et al.* Wnt signaling arrests effector T cell differentiation and generates CD8<sup>+</sup> memory stem cells. *Nat. Med.* **15**, 808–813 (2009).
19. Gattinoni, L. *et al.* A human memory T cell subset with stem cell-like properties. *Nat. Med.* **17**, 1290–1297 (2011).
20. Lugli, E. *et al.* Identification, isolation and *in vitro* expansion of human and nonhuman primate T stem cell memory cells. *Nat. Protoc.* **8**, 33–42 (2013).
21. Di Benedetto, S. *et al.* Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. *Biogerontology* **16**, 631–643 (2015).
22. Roederer, M. *et al.* The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis. *Cell* **161**, 387–403 (2015).
23. Cieri, N. *et al.* IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. *Blood* **121**, 573–584 (2013).
24. Lugli, E. *et al.* Superior T memory stem cell persistence supports long-lived T cell memory. *J. Clin. Invest.* **123**, 594–599 (2013).
25. Simons, B.D. & Clevers, H. Strategies for homeostatic stem cell self-renewal in adult tissues. *Cell* **145**, 851–862 (2011).
26. Wherry, E.J. *et al.* Lineage relationship and protective immunity of memory CD8 T cell subsets. *Nat. Immunol.* **4**, 225–234 (2003).
27. Graef, P. *et al.* Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8<sup>+</sup> central memory T cells. *Immunity* **41**, 116–126 (2014).
28. Gattinoni, L. Memory T cells officially join the stem cell club. *Immunity* **41**, 7–9 (2014).
29. Gerlach, C. *et al.* Heterogeneous differentiation patterns of individual CD8<sup>+</sup> T cells. *Science* **340**, 635–639 (2013).
30. Buchholz, V.R. *et al.* Disparate individual fates compose robust CD8<sup>+</sup> T cell immunity. *Science* **340**, 630–635 (2013).
31. Lanzavecchia, A. & Sallusto, F. Progressive differentiation and selection of the fittest in the immune response. *Nat. Rev. Immunol.* **2**, 982–987 (2002).
32. Joshi, N.S. *et al.* Inflammation directs memory precursor and short-lived effector CD8<sup>+</sup> T cell fates via the graded expression of T-bet transcription factor. *Immunity* **27**, 281–295 (2007).
33. Cieri, N. *et al.* Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. *Blood* **125**, 2865–2874 (2015).
34. Roberto, A. *et al.* Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. *Blood* **125**, 2855–2864 (2015).
35. Oliveira, G. *et al.* Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. *Sci. Transl. Med.* **7**, 317ra198 (2015).
36. Fuertes Marraco, S.A. *et al.* Long-lasting stem cell-like memory CD8<sup>+</sup> T cells with a naive-like profile upon yellow fever vaccination. *Sci. Transl. Med.* **7**, 282ra48 (2015).
37. Fuertes Marraco, S.A., Sonesson, C., Delorenzi, M. & Speiser, D.E. Genome-wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever vaccination in humans. *Genom. Data* **5**, 297–301 (2015).
38. Biasco, L. *et al.* *In vivo* tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. *Sci. Transl. Med.* **7**, 273ra13 (2015).



39. Xu, Y. *et al.* Closely related T-memory stem cells correlate with in vivo expansion of CAR-CD19-T cells and are preserved by IL-7 and IL-15. *Blood* **123**, 3750–3759 (2014).
40. Vignani, S. *et al.* Prolonged antiretroviral therapy preserves HIV-1-specific CD8 T cells with stem cell-like properties. *J. Virol.* **89**, 7829–7840 (2015).
41. Axelsson-Robertson, R., Ju, J.H., Kim, H.Y., Zumla, A. & Møller, M. *Mycobacterium tuberculosis*-specific and MHC class I-restricted CD8<sup>+</sup> T-cells exhibit a stem cell precursor-like phenotype in patients with active pulmonary tuberculosis. *Int. J. Infect. Dis.* **32**, 13–22 (2015).
42. Mateus, J. *et al.* Low frequency of circulating CD8<sup>+</sup> T stem cell memory cells in chronic chagasic patients with severe forms of the disease. *PLoS Negl. Trop. Dis.* **9**, e3432 (2015).
43. Ahmed, R. & Akondy, R.S. Insights into human CD8<sup>+</sup> T-cell memory using the yellow fever and smallpox vaccines. *Immunol. Cell Biol.* **89**, 340–345 (2011).
44. Speiser, D.E. *et al.* T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? *Nat. Rev. Immunol.* **14**, 768–774 (2014).
45. Utschneider, D.T. *et al.* T cell factor 1-expressing memory-like CD8<sup>+</sup> T cells sustain the immune response to chronic viral infections. *Immunity* **45**, 415–427 (2016).
46. Im, S.J. *et al.* Defining CD8<sup>+</sup> T cells that provide the proliferative burst after PD-1 therapy. *Nature* **537**, 417–421 (2016).
47. Wu, T. *et al.* The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. *Sci. Immunol.* <http://dx.doi.org/10.1126/sciimmunol.aai8593> (2016).
48. Ribeiro, S.P. *et al.* The CD8<sup>+</sup> memory stem T cell (T<sub>SCM</sub>) subset is associated with improved prognosis in chronic HIV-1 infection. *J. Virol.* **88**, 13836–13844 (2014).
49. Cartwright, E.K. *et al.* Divergent CD4<sup>+</sup> T memory stem cell dynamics in pathogenic and nonpathogenic simian immunodeficiency virus infections. *J. Immunol.* **192**, 4666–4673 (2014).
50. Klatt, N.R. *et al.* Limited HIV infection of central memory and stem cell memory CD4<sup>+</sup> T cells is associated with lack of progression in viremic individuals. *PLoS Pathog.* **10**, e1004345 (2014).
51. Cartwright, E.K. *et al.* Initiation of antiretroviral therapy restores CD4<sup>+</sup> T<sub>SCM</sub> homeostasis in SIV-infected macaques. *J. Virol.* **90**, 6699–6708 (2016).
52. Calascibetta, F. *et al.* Antiretroviral therapy in simian immunodeficiency virus-infected sooty mangabeys: implications for AIDS pathogenesis. *J. Virol.* **90**, 7541–7551 (2016).
53. Speiser, D.E. *et al.* Rapid and strong human CD8<sup>+</sup> T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. *J. Clin. Invest.* **115**, 739–746 (2005).
54. Melero, I. *et al.* Therapeutic vaccines for cancer: an overview of clinical trials. *Nat. Rev. Clin. Oncol.* **11**, 509–524 (2014).
55. De Gregorio, E. & Rappuoli, R. Vaccines for the future: learning from human immunology. *Microb. Biotechnol.* **5**, 149–155 (2012).
56. Chang, J.T., Wherry, E.J. & Goldrath, A.W. Molecular regulation of effector and memory T cell differentiation. *Nat. Immunol.* **15**, 1104–1115 (2014).
57. Pham, N.L., Badovinac, V.P. & Harty, J.T. A default pathway of memory CD8 T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation. *J. Immunol.* **183**, 2337–2348 (2009).
58. Gannon, P. *et al.* Rapid and continued T cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients. *Clin. Cancer Res.* <http://dx.doi.org/10.1158/1078-0432.CCR-16-1708> (2016).
59. Park, C.O. & Kupper, T.S. The emerging role of resident memory T cells in protective immunity and inflammatory disease. *Nat. Med.* **21**, 688–697 (2015).
60. Mackay, L.K. *et al.* T-box transcription factors combine with the cytokines TGF- $\beta$  and IL-15 to control tissue-resident memory T cell fate. *Immunity* **43**, 1101–1111 (2015).
61. Zhang, N. & Bevan, M.J. Transforming growth factor- $\beta$  signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. *Immunity* **39**, 687–696 (2013).
62. Jameson, S.C. & Masopust, D. Diversity in T cell memory: an embarrassment of riches. *Immunity* **31**, 859–871 (2009).
63. Farber, D.L., Yudanin, N.A. & Restifo, N.P. Human memory T cells: generation, compartmentalization and homeostasis. *Nat. Rev. Immunol.* **14**, 24–35 (2014).
64. Gattinoni, L. The dark side of T memory stem cells. *Blood* **125**, 3519–3520 (2015).
65. Hosokawa, K. *et al.* Memory stem T cells in autoimmune disease: high frequency of circulating CD8<sup>+</sup> memory stem cells in acquired aplastic anemia. *J. Immunol.* **196**, 1568–1578 (2016).
66. Monti, P., Heninger, A.K. & Bonifacio, E. Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. *Curr. Diab. Rep.* **9**, 113–118 (2009).
67. Tabler, C.O. *et al.* CD4<sup>+</sup> memory stem cells are infected by HIV-1 in a manner regulated in part by SAMHD1 expression. *J. Virol.* **88**, 4976–4986 (2014).
68. Buzon, M.J. *et al.* HIV-1 persistence in CD4<sup>+</sup> T cells with stem cell-like properties. *Nat. Med.* **20**, 139–142 (2014).
69. Jaafoura, S. *et al.* Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4<sup>+</sup> memory T cells. *Nat. Commun.* **5**, 5407 (2014).
70. Nagai, Y. *et al.* T memory stem cells are the hierarchical apex of adult T-cell leukemia. *Blood* **125**, 3527–3535 (2015).
71. Rosenberg, S.A. & Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. *Science* **348**, 62–68 (2015).
72. June, C.H., Riddell, S.R. & Schumacher, T.N. Adoptive cellular therapy: a race to the finish line. *Sci. Transl. Med.* **7**, 280ps7 (2015).
73. Dudley, M.E. *et al.* Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* **298**, 850–854 (2002).
74. Brentjens, R.J. *et al.* CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci. Transl. Med.* **5**, 177ra38 (2013).
75. Lee, D.W. *et al.* T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *Lancet* **385**, 517–528 (2015).
76. Kochenderfer, J.N. *et al.* Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J. Clin. Oncol.* **33**, 540–549 (2015).
77. Brudno, J.N. *et al.* Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. *J. Clin. Oncol.* **34**, 1112–1121 (2016).
78. Maude, S.L. *et al.* Chimeric antigen receptor T cells for sustained remissions in leukemia. *N. Engl. J. Med.* **371**, 1507–1517 (2014).
79. Porter, D.L. *et al.* Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci. Transl. Med.* **7**, 303ra139 (2015).
80. Robbins, P.F. *et al.* A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. *Clin. Cancer Res.* **21**, 1019–1027 (2015).
81. Robbins, P.F. *et al.* Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. *J. Immunol.* **173**, 7125–7130 (2004).
82. Pule, M.A. *et al.* Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nat. Med.* **14**, 1264–1270 (2008).
83. Rosenberg, S.A. *et al.* Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin. Cancer Res.* **17**, 4550–4557 (2011).
84. Kalos, M. *et al.* T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci. Transl. Med.* **3**, 95ra73 (2011).
85. Stevanović, S. *et al.* Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. *J. Clin. Oncol.* **33**, 1543–1550 (2015).
86. Turtle, C.J. *et al.* Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8<sup>+</sup> and CD4<sup>+</sup> CD19-specific chimeric antigen receptor-modified T cells. *Sci. Transl. Med.* **8**, 355ra116 (2016).
87. Busch, D.H., Fräßle, S.P., Sommermeyer, D., Buchholz, V.R. & Riddell, S.R. Role of memory T cell subsets for adoptive immunotherapy. *Semin. Immunol.* **28**, 28–34 (2016).
88. Zhou, J. *et al.* Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. *J. Immunol.* **175**, 7046–7052 (2005).
89. Huang, J. *et al.* Modulation by IL-2 of CD70 and CD27 expression on CD8<sup>+</sup> T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. *J. Immunol.* **176**, 7726–7735 (2006).
90. Louis, C.U. *et al.* Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood* **118**, 6050–6056 (2011).
91. Gattinoni, L. *et al.* Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8<sup>+</sup> T cells. *J. Clin. Invest.* **115**, 1616–1626 (2005).
92. Klebanoff, C.A. *et al.* Central memory self/tumor-reactive CD8<sup>+</sup> T cells confer superior antitumor immunity compared with effector memory T cells. *Proc. Natl. Acad. Sci. USA* **102**, 9571–9576 (2005).
93. Hinrichs, C.S. *et al.* Adoptively transferred effector cells derived from naive rather than central memory CD8<sup>+</sup> T cells mediate superior antitumor immunity. *Proc. Natl. Acad. Sci. USA* **106**, 17469–17474 (2009).
94. Wang, X. *et al.* Comparison of naive and central memory derived CD8<sup>+</sup> effector cell engraftment fitness and function following adoptive transfer. *Oncol Immunology* **5**, e1072671 (2015).
95. Sommermeyer, D. *et al.* Chimeric antigen receptor-modified T cells derived from defined CD8<sup>+</sup> and CD4<sup>+</sup> subsets confer superior antitumor reactivity in vivo. *Leukemia* **30**, 492–500 (2016).
96. Klebanoff, C.A. *et al.* Determinants of successful CD8<sup>+</sup> T-cell adoptive immunotherapy for large established tumors in mice. *Clin. Cancer Res.* **17**, 5343–5352 (2011).
97. Berger, C. *et al.* Adoptive transfer of effector CD8<sup>+</sup> T cells derived from central memory cells establishes persistent T cell memory in primates. *J. Clin. Invest.* **118**, 294–305 (2008).
98. Baitsch, L. *et al.* Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. *J. Clin. Invest.* **121**, 2350–2360 (2011).

99. Gros, A. *et al.* PD-1 identifies the patient-specific CD8 tumor-reactive repertoire infiltrating human tumors. *J. Clin. Invest.* **124**, 2246–2259 (2014).
100. Lugli, E. *et al.* Subject classification obtained by cluster analysis and principal component analysis applied to flow cytometric data. *Cytometry A* **71**, 334–344 (2007).
101. Appay, V. *et al.* Memory CD8<sup>+</sup> T cells vary in differentiation phenotype in different persistent virus infections. *Nat. Med.* **8**, 379–385 (2002).
102. Mackall, C.L. *et al.* Distinctions between CD8<sup>+</sup> and CD4<sup>+</sup> T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. *Blood* **89**, 3700–3707 (1997).
103. Singh, N., Perazzelli, J., Grupp, S.A. & Barrett, D.M. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. *Sci. Transl. Med.* **8**, 320ra3 (2016).
104. Turtle, C.J. *et al.* CD19 CAR-T cells of defined CD4<sup>+</sup>:CD8<sup>+</sup> composition in adult B cell ALL patients. *J. Clin. Invest.* **126**, 2123–2138 (2016).
105. Wang, X. *et al.* Phase 1 studies of central-memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. *Blood* **24**, 2980–2990 (2016).
106. Li, Q. *et al.* A central role for mTOR kinase in homeostatic proliferation induced CD8<sup>+</sup> T cell memory and tumor immunity. *Immunity* **34**, 541–553 (2011).
107. Hinrichs, C.S. *et al.* IL-2 and IL-21 confer opposing differentiation programs to CD8<sup>+</sup> T cells for adoptive immunotherapy. *Blood* **111**, 5326–5333 (2008).
108. van der Waart, A.B. *et al.* Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. *Blood* **124**, 3490–3500 (2014).
109. Crompton, J.G. *et al.* Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. *Cancer Res.* **75**, 296–305 (2015).
110. Gattinoni, L., Klebanoff, C.A. & Restifo, N.P. Pharmacologic induction of CD8<sup>+</sup> T cell memory: better living through chemistry. *Sci. Transl. Med.* **1**, 11ps12 (2009).
111. Davila, M.L. *et al.* Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci. Transl. Med.* **6**, 224ra25 (2014).
112. Grupp, S.A. *et al.* Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N. Engl. J. Med.* **368**, 1509–1518 (2013).
113. Sabatino, M. *et al.* Generation of clinical-grade CD19-specific CAR-modified CD8<sup>+</sup> memory stem cells for the treatment of human B-cell malignancies. *Blood* **128**, 519–528 (2016).
114. Klebanoff, C.A. *et al.* Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. *J. Clin. Invest.* **126**, 318–334 (2016).
115. Klebanoff, C.A., Gattinoni, L. & Restifo, N.P. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? *J. Immunother.* **35**, 651–660 (2012).
116. Ding, Z.C. *et al.* IL-7 signaling imparts polyfunctionality and stemness potential to CD4<sup>+</sup> T cells. *Oncol Immunology* **5**, e1171445 (2016).
117. Provasi, E. *et al.* Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. *Nat. Med.* **18**, 807–815 (2012).
118. Stemmerger, C. *et al.* Lowest numbers of primary CD8<sup>+</sup> T cells can reconstitute protective immunity upon adoptive immunotherapy. *Blood* **124**, 628–637 (2014).
119. Schmueck-Henneresse, M. *et al.* Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency. *J. Immunol.* **194**, 5559–5567 (2015).
120. Terakura, S. *et al.* Generation of CD19-chimeric antigen receptor modified CD8<sup>+</sup> T cells derived from virus-specific central memory T cells. *Blood* **119**, 72–82 (2012).
121. Becker, T.C. *et al.* Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. *J. Exp. Med.* **195**, 1541–1548 (2002).
122. Schluns, K.S., Williams, K., Ma, A., Zheng, X.X. & Lefrançois, L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. *J. Immunol.* **168**, 4827–4831 (2002).
123. Yi, J.S., Du, M. & Zajac, A.J. A vital role for interleukin-21 in the control of a chronic viral infection. *Science* **324**, 1572–1576 (2009).
124. Fröhlich, A. *et al.* IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. *Science* **324**, 1576–1580 (2009).
125. Yi, J.S., Ingram, J.T. & Zajac, A.J. IL-21 deficiency influences CD8 T cell quality and recall responses following an acute viral infection. *J. Immunol.* **185**, 4835–4845 (2010).
126. Cui, W., Liu, Y., Weinstein, J.S., Craft, J. & Kaech, S.M. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8<sup>+</sup> T cells. *Immunity* **35**, 792–805 (2011).
127. van der Windt, G.J. *et al.* Mitochondrial respiratory capacity is a critical regulator of CD8<sup>+</sup> T cell memory development. *Immunity* **36**, 68–78 (2012).
128. Sukumar, M. *et al.* Inhibiting glycolytic metabolism enhances CD8<sup>+</sup> T cell memory and antitumor function. *J. Clin. Invest.* **123**, 4479–4488 (2013).
129. Liu, L. *et al.* Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. *J. Virol.* **89**, 6685–6694 (2015).
130. Ali, A. *et al.* HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. *J. Virol.* **90**, 6999–7006 (2016).
131. Gattinoni, L. & Restifo, N.P. Moving T memory stem cells to the clinic. *Blood* **121**, 567–568 (2013).
132. Kahn, M. Can we safely target the WNT pathway? *Nat. Rev. Drug Discov.* **13**, 513–532 (2014).
133. Ramishetti, S. *et al.* Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. *ACS Nano* **9**, 6706–6716 (2015).
134. Zhou, J. *et al.* Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. *Nucleic Acids Res.* **37**, 3094–3109 (2009).
135. Tebas, P. *et al.* Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. *N. Engl. J. Med.* **370**, 901–910 (2014).
136. Dragic, T. *et al.* HIV-1 entry into CD4<sup>+</sup> cells is mediated by the chemokine receptor CC-CKR-5. *Nature* **381**, 667–673 (1996).
137. Scholz, G. *et al.* Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells. *EBioMedicine* **4**, 50–61 (2016).
138. Crompton, J.G. *et al.* Lineage relationship of CD8<sup>+</sup> T cell subsets is revealed by progressive changes in the epigenetic landscape. *Cell. Mol. Immunol.* **13**, 502–513 (2016).
139. Chang, J.T. *et al.* Asymmetric proteasome segregation as a mechanism for unequal partitioning of the transcription factor T-bet during T lymphocyte division. *Immunity* **34**, 492–504 (2011).
140. Lin, W.H. *et al.* Asymmetric PI3K signaling driving developmental and regenerative cell fate bifurcation. *Cell Reports* **13**, 2203–2218 (2015).
141. Verbist, K.C. *et al.* Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. *Nature* **532**, 389–393 (2016).
142. Pollizzi, K.N. *et al.* Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8<sup>+</sup> T cell differentiation. *Nat. Immunol.* **17**, 704–711 (2016).
143. Jeannot, G. *et al.* Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. *Proc. Natl. Acad. Sci. USA* **107**, 9777–9782 (2010).
144. Zhou, X. *et al.* Differentiation and persistence of memory CD8<sup>+</sup> T cells depend on T cell factor 1. *Immunity* **33**, 229–240 (2010).
145. Zhao, D.M. *et al.* Constitutive activation of Wnt signaling favors generation of memory CD8 T cells. *J. Immunol.* **184**, 1191–1199 (2010).
146. Boudousquie, C. *et al.* Differences in the transduction of canonical Wnt signals demarcate effector and memory CD8 T cells with distinct recall proliferation capacity. *J. Immunol.* **193**, 2784–2791 (2014).
147. Araki, K. *et al.* mTOR regulates memory CD8 T-cell differentiation. *Nature* **460**, 108–112 (2009).
148. Rao, R.R., Li, Q., Odunsi, K. & Shrikant, P.A. The mTOR kinase determines effector versus memory CD8<sup>+</sup> T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. *Immunity* **32**, 67–78 (2010).
149. Pearce, E.L., Poffenberger, M.C., Chang, C.H. & Jones, R.G. Fueling immunity: insights into metabolism and lymphocyte function. *Science* **342**, 1242454 (2013).
150. van der Windt, G.J. *et al.* CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. *Proc. Natl. Acad. Sci. USA* **110**, 14336–14341 (2013).
151. Sukumar, M. *et al.* Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. *Cell Metab.* **23**, 63–76 (2016).
152. Buck, M.D. *et al.* Mitochondrial dynamics controls T cell fate through metabolic programming. *Cell* **166**, 63–76 (2016).
153. Morrison, S.J. & Spradling, A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. *Cell* **132**, 598–611 (2008).
154. Di Rosa, F. Two niches in the bone marrow: a hypothesis on life-long T cell memory. *Trends Immunol.* **37**, 503–512 (2016).
155. Alp, Ö.S. *et al.* Memory CD8<sup>+</sup> T cells colocalize with IL-7<sup>+</sup> stromal cells in bone marrow and rest in terms of proliferation and transcription. *Eur. J. Immunol.* **45**, 975–987 (2015).
156. Becker, T.C., Coley, S.M., Wherry, E.J. & Ahmed, R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. *J. Immunol.* **174**, 1269–1273 (2005).
157. Mazo, I.B. *et al.* Bone marrow is a major reservoir and site of recruitment for central memory CD8<sup>+</sup> T cells. *Immunity* **22**, 259–270 (2005).
158. Takada, K. & Jameson, S.C. Naive T cell homeostasis: from awareness of space to a sense of place. *Nat. Rev. Immunol.* **9**, 823–832 (2009).